| 王建材,李立宏,李玉骞,段凤菊,高国栋,张 卓.阿托伐他汀钙对帕金森病细胞模型的保护作用及其临床意义[J].,2020,(8):1473-1476 |
| 阿托伐他汀钙对帕金森病细胞模型的保护作用及其临床意义 |
| The Protective Effect of Atorvastatin Calcium in Parkinson's Disease in Vitro Study and Its Clinical Significance |
| 投稿时间：2019-11-10 修订日期：2019-12-06 |
| DOI：10.13241/j.cnki.pmb.2020.08.015 |
| 中文关键词: 帕金森病 阿托伐他汀钙 Wnt通路 盐酸普拉克索 多巴丝肼片 |
| 英文关键词: Parkinson's disease Atorvastatin Wnt signaling Pramipexole Levodopa and Benserazide Tablets |
| 基金项目:国家自然科学基金青年科学基金项目（83100928）；全军医学科技青年培育计划拔尖项目（18QNP027） |
|
| 摘要点击次数: 734 |
| 全文下载次数: 552 |
| 中文摘要: |
| 摘要 目的：评价阿托伐他汀钙对帕金森病细胞模型及帕金森病患者临床症状的影响。方法：首先使用MPP+处理SH-SY5Y细胞建立帕金森病细胞模型。观察阿托伐他汀钙在该模型中对Wnt通路以及细胞凋亡的影响。其次选取66例符合纳入标准的临床患者，其中33例服用多巴丝肼片和盐酸普拉克索（普通治疗组）。其余33例则因其他原因在使用多巴丝肼片和盐酸普拉克索治疗期间服用阿托伐他汀钙片（阿托伐他汀组）。观察两组患者的Hoehn -Yahr分级，UPDRS评分，以及不良反应的发生率。结果：在MPP+处理组，Wnt通路受到抑制且细胞发生凋亡，而阿托伐他汀钙预处理可缓解MPP+引起的Wnt通路的抑制和细胞凋亡，差异具有统计学意义（P＜0.05）。治疗8周后阿托伐他汀组的Hoehn -Yahr分级改善情况显著优于普通治疗组的改善情况，并且差异具有统计学意义（P＜0.05）；治疗8周后普通治疗组的UPDRS评分高于阿托伐他汀组的评分，差异具有统计学意义（P＜0.05）；阿托伐他汀组的不良反应发生率低于普通治疗组，但差异无统计学意义（P＞0.05）。结论：阿托伐他汀钙可通过Wnt通路保护MPP+引起的细胞凋亡并且在临床治疗中能较好的改善帕金森病患者的运动和非运动症状。 |
| 英文摘要: |
| ABSTRACT Objective: To evaluate the clinical efficacy of Atorvastatin calcium of the treatment on Parkinson's disease (PD) and its mechanism. Methods: Firstly, the effect of atorvastatin calcium on Wnt Signaling and cell apoptosis in MPP+-treated SH-SY5Y cells were analyzed. 66 patients of PD were collected and divided into two groups. The normal treatment group was treated with pramipexole combined with Levodopa and Benserazide Tablets. The Atorva group was treated with Atorvastatin calcium, pramipexole, and Levodopa and Benserazide Tablets. The Hoehn -Yahr Grade, UPDRS scores, and the incidence of adverse reactions were observed. Results: MPP+ treatment induced the down-regulation of Wnt signaling and cell apoptosis in SH-SY5Y cells and the pretreatment of atorvastatin calcium could abrogate this effect. The Hoehn -Yahr Grade were significantly improved in Atorva group compared with normal treatment group after 8 weeks treatment（P＜0.05）. The scores of UPDRS decreased significantly in Atorva group compared with normal treatment group after 8 weeks treatment（P＜0.05）. The incidence of adverse reactions showed no difference in Atorva group and normal treatment group（P＞0.05）. Conclusion: Atorvastatin calcium could protect the SH-SY5Y cells from MPP+-induced cell apoptosis via Wnt signaling and PD patients treated with Atorvastatin can improve the motor symptoms, non-motor symptoms. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
